趋化素样因子超家族成员6在胶质瘤中的表达及临床意义

Expression and clinical significance of chemokine-like factor 6 in glioma

目的:探究趋化素样因子超家族成员6(CMTM6)在胶质瘤中的表达及临床意义。方法:采用免疫组化、免疫荧光、Western blot和qRT-PCR检测CMTM6在胶质瘤组织和细胞系中的表达。结果:CMTM6表达于神经胶质细胞的胞质和胞膜;在胶质瘤组织和胶质母细胞瘤细胞系(U87、U251)中CMTM6的表达均高于正常脑组织和人脑正常胶质细胞系(HEB);高级别组阳性表达率高于低级别组;CMTM6高表达患者的总生存期和无病生存期均比低表达患者明显缩短;年龄、病理分级和CMTM6的表达水平均是评判胶质瘤预后的独立危险因素。结论:CMTM6在胶质瘤中高表达,可作为胶质瘤患者预后评判的独立危险因子。

Objective:To investigate the expression and clinical significance of chemokine-like factor 6(CMTM6) in glioma.Methods:The expression of CMTM6 in glioma tissues and cell lines was detected by immunohistochemistry,immunofluorescence,Western blot and qRT-PCR.Results:CMTM6 was expressed in the cytoplasm and membrane of glial cells.The expression of CMTM6 in glioma tissues and glioblastoma cell lines(U87 and U251) was higher than that in normal brain tissues and human brain normal glial cell lines(HEB).The positive expression rate of the high-level group was higher than that of the low-level group.The overall survival and disease-free survival of patients with high expression of CMTM6 were significantly shorter than those with low expression.Age,pathological grade and CMTM6 expression were independent risk factors for glioma prognosis.Conclusion:CMTM6 is highly expressed in glioma and can be used as an independent risk factor for prognosis evaluation of glioma.